DXCM SHAREHOLDER ALERT: Upcoming Class Action Deadline in DexCom, Inc. Case is Approaching; Contact BFA Law before October 21 (Nasdaq:DXCM)
October 03, 2024 07:15 ET
|
Bleichmar Fonti & Auld
DexCom, Inc. investors that lost money on their investment are encouraged to contact BFA Law before October 21, 2024 legal deadline.
DXCM INVESTOR NOTICE: DexCom, Inc. Investors that Suffered Losses are Notified to Contact BFA Law before October 21 Class Action Deadline (Nasdaq:DXCM)
October 01, 2024 06:43 ET
|
Bleichmar Fonti & Auld
DexCom, Inc. investors that lost money on their investment are encouraged to contact BFA Law before October 21, 2024 legal deadline.
LeaderMed Group and Combiphar Form Joint Venture on LM-008, a Novel GLP-1 Dual Agonist, Targeting Indonesia's High Diabetes and/or Obesity Prevalence
September 30, 2024 22:00 ET
|
LeaderMed Group; Combiphar
LeaderMed and Combiphar form a joint venture to tackle Indonesia’s diabetes and obesity crisis with LM-008 and UltraSculpt, launching a Phase 3 trial.
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
September 30, 2024 06:00 ET
|
MannKind
MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS
OR AUTOMATED PUMPS TO INHALED INSULIN
DXCM STOCK UPDATE: Investors of DexCom, Inc. are Alerted of Imminent October 21 Deadline; Contact BFA Law if You Lost Money (Nasdaq:DXCM)
September 29, 2024 06:31 ET
|
Bleichmar Fonti & Auld
DexCom, Inc. investors that lost money on their investment are encouraged to contact BFA Law before October 21, 2024 legal deadline.
DXCM FRAUD NOTICE: The October 21 Court Deadline in the DexCom, Inc. Class Action is Approaching – Contact BFA Law if You Suffered Losses (Nasdaq:DXCM)
September 27, 2024 06:16 ET
|
Bleichmar Fonti & Auld
DexCom, Inc. investors that lost money on their investment are encouraged to contact BFA Law before October 21, 2024 legal deadline.
Type 2 Diabetes in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction
September 26, 2024 04:19 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Type 2 Diabetes in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ...
DXCM OCTOBER 21 DEADLINE: DexCom, Inc. has been Sued for Securities Fraud; Contact BFA Law before October 21Court Deadline (Nasdaq:DXCM)
September 25, 2024 07:13 ET
|
Bleichmar Fonti & Auld
DexCom, Inc. investors that lost money on their investment are encouraged to contact BFA Law before October 21, 2024 legal deadline.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
DXCM DEADLINE NOTICE: DexCom, Inc. has been Sued for Securities Fraud; Investors that Lost Money are Urged to Contact BFA Law by October 21 (Nasdaq:DXCM)
September 23, 2024 06:17 ET
|
Bleichmar Fonti & Auld
DexCom, Inc. investors that lost money on their investment are encouraged to contact BFA Law before October 21, 2024 legal deadline.